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Melioidosis is a neglected tropical disease with an estimated annual global mortality rate of 89,000 
(1). Its cause is the gram-negative bacterium Burkhold-
eria pseudomallei, which is found in environmental soil 
and water in Southeast Asia and northern Australia 
and is increasingly recognized across tropical regions 
(2). Known underlying risk factors that contribute to 
increased susceptibility to infection include diabe-
tes, chronic kidney diseases, and alcohol abuse (3). 
The rapid expansion of type 2 diabetes, especially in 
low- and middle-income countries, is likely to exacer-
bate the situation further (4). In Thailand, B. pseudo-
mallei is highly distributed in the environment in the 
northeast, where most of the country’s melioidosis 
cases have been reported (5). However, B. pseudomal-
lei is also isolated from soil in the eastern and central 
parts of Thailand. A closely related species of mini-
mal virulence, B. thailandensis, and a B. thailandensis 
variant (BTCV) expressing the B. pseudomallei–like 
capsular polysaccharide (CPS) are also present in the 
soil in Thailand (6). The genomic composition of B. 
thailandensis shows >85% similarity with B. pseudo-
mallei (7). However, there are a few key differences, 
including the lack of virulence factors, such as capsu-
lar polysaccharide, and the presence of the arabinose 
assimilation operon (8) in B. thailandensis and BTCV. 
The hybrid BTCV exhibits several features found in B. 
pseudomallei, including resistance to decomposition by 
the complement system, intracellular survival inside 
macrophages, and colony morphology that resembles 
that of B. pseudomallei (9). Although BTCV has ac-
quired B. pseudomallei–like CPS gene clusters, it has 
been shown to be nonpathogenic in mouse models (9).
Immune cross-protection conferred by B. thai-
landensis variants has been demonstrated in animal 
models (10). In particular, mice immunized with the 
BTCV isolate E555 showed superior cross-protection 
to that from the noncapsulated strain against a lethal 
dose of B. pseudomallei challenge, resulting in high 
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Melioidosis is a neglected tropical disease with an es-
timated annual mortality rate of 89,000 in 45 countries 
across tropical regions. The causative agent is Burkhold-
eria pseudomallei, a gram-negative soil-dwelling bacte-
rium. In Thailand, B. pseudomallei can be found across 
multiple regions, along with the low-virulence B. thai-
landensis and the recently discovered B. thailandensis 
variant (BTCV), which expresses B. pseudomallei–like 
capsular polysaccharide. Comprehensive studies of hu-
man immune responses to B. thailandensis variants and 
cross-reactivity to B. pseudomallei are not complete. We 
evaluated human immune responses to B. pseudomallei, 
B. thailandensis, and BTCV in melioidosis patients and 
healthy persons in B. pseudomallei–endemic areas us-
ing a range of humoral and cellular immune assays. We 
found immune cross-reactivity to be strong for both hu-
moral and cellular immunity among B. pseudomallei, B. 
thailandensis, and BTCV. Our findings suggest that en-
vironmental exposure to low-virulence strains may build 
cellular immunity to B. pseudomallei. 
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CPS-specific IgG levels and decreased bacterial prev-
alence (10). To date, comprehensive immune cross-
reactivity to B. thailandensis and BTCV has not been 
studied in humans.
Protective adaptive immunity in human melioi-
dosis is complex, but defense against its intracellular 
pathogen is likely to require competent cellular im-
mune responses largely mediated by T lymphocytes 
(11,12). Our team and others have shown that surviv-
ing melioidosis patients have elevated CD4 and CD8 
T-cell–mediated interferon γ (IFN-γ) responses to B. 
pseudomallei compared with deceased case-patients 
(13,14). Along with key protective immunity con-
ferred by cellular immune responses, humoral im-
munity against BP infection has been demonstrated 
to be a component of protection in rodent models 
(15), although antibody levels measured by indirect 
hemagluttination assay were not significantly associ-
ated with survival (p>0.05) in human patients after 
adjusting for other parameters (16). Our study aimed 
to characterize the relationship between the human B. 
pseudomallei–specific immune response and responses 
to B. thailandensis and BTCV. We evaluated humoral 
and cellular immune responses to B. pseudomallei, B. 
thailandensis, and BTCV in patients with acute melioi-
dosis, in patients with other gram-negative bacterial 
infections, and in exposed populations in the endemic 
region with and without diabetes.
Materials and Methods
Study Design
We conducted a prospective observational study dur-
ing 2015–2017 at Sunpasitthiprasong Hospital, Ubon 
Ratchathani, Thailand, to evaluate human immune re-
sponses to B. pseudomallei, B. thailandensis, and BTCV. 
We recruited 4 cohorts: inpatients >20 years of age 
who had culture-confirmed melioidosis (melioidosis 
cohort; n = 99), patients who had positive cultures 
for other gram-negative bacterial infections (OGNI 
cohort; n = 48), patients who attended the hospital’s 
diabetes outpatient clinic for diabetes mellitus (DM 
cohort; n = 98), and healthy control participants from 
the melioidosis-endemic areas who were household 
contacts of the melioidosis case-patients (HH cohort; 
n = 96). The number of samples varied between as-
says due to sample availability (Table 1). We deter-
mined 28-day survival status using the hospital death 
records and by telephone. We collected blood samples 
during enrollment and processed them as described 
previously (13). We measured humoral and cellu-
lar immune responses using indirect hemagglutina-
tion assay (IHA), IgM and IgG ELISA, ex vivo IFN-γ 
enzyme-linked immunospot assay (IFN-γ ELISpot), 
and a whole-blood stimulation assay (WBA). The eth-
ics committees of the Faculty of Tropical Medicine, 
Mahidol University (TMEC 12–014); Sunpasitthip-
rasong Hospital, Ubon Ratchathani (017/2559); and 
the Oxford Tropical Research Ethics Committee (OX-
TREC35–15) approved the study protocol.
Antigen Preparation
We prepared antigens in accordance with published 
methods, unless otherwise stated (17,18). For IHA, we 
used crude culture filtrate antigens from pooled iso-
lates with the following specifications: B. pseudomallei 
Thai clinical isolates 199a and 207a (19), B. thailand-
ensis Thai environmental isolates E264 (ATCC700388) 
and STBCC006 (20), and BTCV Thai environmental 
E555 and USA clinical isolate CDC3015869. We pre-
pared B. thailandensis and BTCV antigens following 
a traditional IHA antigen preparation as described 
previously (17). For ELISA, we prepared whole-cell 
heat-killed antigens from B. pseudomallei Thai clinical 
isolate K96243, BT E264, and BTCV E555 as described 
previously (18). For IFN-γ ELISpot and whole-blood 
stimulation assay, we used a single culture filtrate an-
tigen of each strain, B. pseudomallei 199a, B. thailanden-
sis E264, and BTCV E555.
IHA and ELISA
We determined serologic responses to B. pseudomal-
lei, B. thailandensis, and BTCV by IHA, as well as IgM 
and IgG ELISA (18). We performed IHA as described 
previously (17), with an IHA titer of >1:80 considered 
positive (21).
IFN-γ ELISpot
We used a commercial IFN-γ ELISpot assay (Mabtech 
AB, https://www.mabtech.com) to quantify secreted 
 
Table 1. Proportions of samples from 4 patient and control cohorts used to evaluate immune responses to melioidosis, Thailand* 
Cohort 
No. (%) samples by assay 
IHA or ELISA IFN-γ ELISpot WBA 
Melioidosis, n = 99 73 (74) 82 (83) 13 (13) 
Healthy household contacts, n = 96 35 (36) 93 (97) 8 (8) 
Diabetes control, n = 98 54 (55) 95 (97) NA 
Other gram-negative bacterial infections, n = 48 10 (20) 42 (88) NA 
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IFN-γ from peripheral blood mononuclear cell 
(PBMC) in response to B. pseudomallei, B. thailanden-
sis, and BTCV antigens as described previously (13). 
In brief, we added PBMC at a density of 2 × 105 cells 
per well to each of 2 antibody-coated plates and in-
cubated them either in media only or in the presence 
of antigen for 18–20 h at 37°C: final concentration 
for B. pseudomallei was 88 µg/mL; for B. thailanden-
sis, 78 µg/mL; for BTCV, 83 µg/mL; and for puri-
fied protein derivative (PPD), 20 µg/mL. We added 
1 µg/mL of detector antibody and incubated for 3 h 
at room temperature, then for 2 h with streptavidin-
conjugated ALP at room temperature. We used the 
AP Conjugate Substrate Kit (Bio-Rad, https://www.
bio-rad.com) to develop spots for up to 20 min. We 
analyzed plates on the CTL ELISpot Reader (CTL 
Analyzers, http://www.immunospot.com) using the 
proprietary Smartcount automated settings. Results 
were reported as spot-forming units (SFU) per mil-
lion PBMC. Background (PBMC in media only) re-
sponses in unstimulated control wells were typically 
<20 spots and were subtracted from those measured 
in antigen-stimulated wells. We used phytohemag-
glutinin (PHA) at a concentration of 10 μg/mL as a 
positive control.
WBA
For antigen stimulation, we added 500 μL hepa-
rinized blood to a 5 mL polystyrene round-bottom 
tube (Corning, https://www.corning.com) contain-
ing a final concentration of 1 μL/mL anti-human 
CD28 and CD49d (Becton Dickinson, https://www.
bd.com), along with B. pseudomallei, B. thailanden-
sis, or BTCV antigens, all at a final concentration of 
1 mg/mL. We used staphylococcal enterotoxin B 
(SEB) at a final concentration of 10 µg/mL as posi-
tive control and RPMI medium supplemented with 
10% fetal bovine serum (FBS) (R10 medium) as neg-
ative control. We incubated the tubes at 37°C, 5% 
CO2, 95% humidity. After 18 h, we added a final con-
centration of 10 μL/mL Brefeldin A (eBioscience, 
https://www.thermofisher.com) and incubated the 
assay for another 4–5 h under the same conditions. 
We then incubated samples with Live/Dead (LD) 
Fixable Near-IR Dead Cell Stain (Life Technologies, 
https://www.thermofisher.com) according to the 
manufacturer’s instructions, followed by a single 
10-min incubation with FACS Lysing solution at 
room temperature for red cell removal (Becton Dick-
inson). We cryopreserved lysed blood cells in FBS 
with 10% dimethylsulfoxide (DMSO) (Sigma Al-
drich, https://www.sigmaaldrich.com) and stored 
at −80°C until flow cytometry staining.
Flow Cytometry
We thawed frozen cells at 37°C and washed them twice 
with R10 medium, then fixed for 20 min followed by 5 
min of permeabilization using BD Cytofix/Cytoperm 
kit (Becton Dickinson). Then, we stained samples 
with fluorescently labeled human antibodies for 20 
min on ice in the dark: CD3-PerCP (clone: UCHT1; 
BioLegend, https://www.biolegend.com), CD4-V450 
(clone: L200, Becton Dickinson), CD8-BV510 (clone: 
RPA-T8; BioLegend), CD56-VioBrightFITC (clone: 
AF12–7H3; Miltenyi Biotec, https://www.milteny-
ibiotec.com), and IFN-γ-PE (clone: 4S.B3; BioLegend). 
We then analyzed using a MACSQuant Analyzer 10 
(Miltenyi Biotec) and performed flow cytometry anal-
ysis using FlowJo software version 10.2 on Mac OS X 
(Becton Dickinson, https://www.flowjo.com).
Statistical Analysis
The outcomes of interest were correlation between 
level of immune responses (measured by IHA titers, 
optical density of IgM and IgG by ELISA and levels 
of cytokine-producing cells, and IFN-γ SFU) against 3 
antigens: B. pseudomallei, B. thailandensis, and BTCV. 
We used Spearman’s correlation coefficient (ρ) to 
determine the correlation between the levels of im-
mune responses against the 3 antigens. We compared 
ordinal and continuous variables using a nonpara-
metric Mann-Whitney test (comparing 2 independent 
groups) and Wilcoxon matched-pairs signed rank test 
(comparing multiple tests on matched cases). We per-
formed all statistical tests using GraphPad Prism ver-




We enrolled a total of 100 patients with culture-con-
firmed melioidosis during April 2016–November 
2017 into the melioidosis cohort. We excluded 1 pa-
tient because of a positive concurrent diagnosis of tu-
berculosis. We recruited participants at a median of 
5 days after admission (interquartile range [IQR] 4–6 
days) (Table 2). Diabetes was an underlying condition 
for two thirds (67%) of the melioidosis cohort. The 
overall 28-day mortality rate was 30% (30/99), with 
no significant difference (p = 0.9) for patients with 
and without diabetes.
Humoral Immune Responses by IHA against  
B. pseudomallei, B. thailandensis, and BTCV
We observed seropositivity against B. pseudomallei in 
58% (42/73) of the melioidosis cohort, 26% (9/35) of 
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HH, 7% (4/54) of DM, and none (0/10) of OGNI. The 
median IHA titer against B. pseudomallei in the meli-
oidosis cohort (median 1:80, interquartile range [IQR] 
1:10–1:320) was higher than that from all control co-
horts (HH, median ≤1:10, IQR ≤1:10–1:80; DM and 
OGNI, median ≤1:10, IQR ≤1:10–1:10; p<0.01). We ob-
served detectable IHA titer against BTCV only in the 
melioidosis cohort (median 1:80, IQR 1:10–1:320); this 
result was significantly higher than that for all con-
trol cohorts (p<0.01) (Figure 1). We observed strong 
correlation between B. pseudomallei and BTCV IHA in 
the melioidosis cohort (ρ = 0.96; p<0.01) and the HH 
cohort (ρ = 0.84; p<0.01). We observed moderate cor-
relation between B. pseudomallei and B. thailandensis 
IHA (ρ = 0.53; p<0.01) only in the melioidosis cohort 
(Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/26/3/19-0206-App1.pdf). We detected no 
responses against B. thailandensis in any of the other 
cohorts (median <1:10).
Humoral Immune Responses by IgG and IgM ELISA 
against B. pseudomallei, B. thailandensis, and BTCV
The melioidosis cohort showed significantly higher 
IgG responses to B. pseudomallei (median of opti-
cal density [OD] = 1.42), B. thailandensis (median 
OD = 1.12), and BTCV (median OD = 1.43) than 
any of the control cohorts (p<0.01) (Figure 2, pan-
el A). IgM responses to B. pseudomallei (median 
OD = 0.48) in the melioidosis cohort, similar to IgG 
responses, were higher than the control cohorts 
(median OD ranges 0.19–0.28, p<0.02). In contrast, 
IgM responses to B. thailandensis and BTCV in the 
melioidosis cohort were similar to responses in the 
HH cohort but higher than those in DM and OGNI 
(p<0.05) (Figure 2, panel B). In the melioidosis co-
hort, we observed a strong correlation from both 
IgM and IgG responses between B. pseudomallei, B. 
thailandensis, and BTCV (ρ>0.9; p<0.01) (Appendix 
Tables 2, 3).
 
Table 2. Characteristics of patients and controls in study of immune responses to melioidosis and cross-reactivity to low-virulence 
Burkholderia species, by cohort, Thailand* 
Baseline characteristics 
Cohort 
Melioidosis, n = 99 Healthy controls, n = 96 
Diabetes controls, 
n = 98* 
Other gram-negative 
bacterial infections, n = 48 
Sex     
 M 63 (64) 27 (28) 25 (26) 27 (56) 
 F 36 (36) 69 (72) 73 (74) 21 (44) 
Age, y, median (range) 55 (20–84) 48 (25–69) 53 (41–60) 64 (24–95) 
Diabetes† 66 (67) NA 98 (100) NA 
Died‡ 30 (30) NA NA NA 
Survived 69 (70) NA NA NA 
*Values are no. (%) except as indicated. 
†Includes patients who were previously diagnosed with diabetes or who have a hemoglobin A1C level >6.5% at time of recruitment. 
‡Died within 28 days of study enrollment. 
 
Figure 1. Humoral immune 
responses to Burkholderia 
pseudomallei, B. thailandensis, 
and BTCV by indirect 
hemagglutination assay, 
Thailand. IHA titers are 
shown for acute melioidosis 
patients (n = 73) and 3 control 
cohorts, HH (n = 35), DM (n = 
54), and OGNI (n = 10), 
against culture-filtrate antigen 
of B. pseudomallei, B. 
thailandensis, and BTCV. Each 
symbol represents an IHA 
titer response from a patient. 
Dotted line indicates the IHA 
cutoff titer for seropositivity. 
Medians (horizontal lines) 
and interquartile ranges (error 
bars) are provided. p values 
were calculated by using 
the nonparametric Mann-
Whitney test. Horizontal bars at top of figure indicate comparisons across cohorts. BTCV, B. thailandensis CPS variant; CPS, capsular 
polysaccharide; DM, patients with diabetes mellitus; HH, healthy household contacts of the melioidosis case-patients; IHA, indirect 
hemagglutination assay.
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Interferon-γ ELISpot Responses to B. pseudomallei,  
B. thailandensis, and BTCV
Quantitatively, IFN-γ responses against B. pseudom-
allei in the melioidosis and HH cohorts were signifi-
cantly higher than those for the DM and OGNI co-
horts (p<0.03). We observed similar outcomes in the 
responses to B. thailandensis and BTCV (Figure 3). 
Of interest, the melioidosis and HH cohorts showed 
comparable IFN-γ responses against B. pseudomallei 
and B. thailandensis, but not to BTCV (p = 0.02) (Fig-
ure 3). In the melioidosis cohort, we observed strong 
correlations between IFN-γ responses to B. pseudom-
allei, B. thailandensis, and BTCV (ρ>0.9; p<0.01). We 
observed similar correlations (ρ>0.7; p<0.01) for the 
HH, OGNI, and DM cohorts (Appendix Table 4).
Cellular Immune Responses to B. pseudomallei,  
B. thailandensis, and BTCV by Whole-Blood  
Stimulation Assay Using Flow Cytometry
To determine the contribution of CD4 T, CD8 T, DN 
T, and NK cells to total IFN-γ responses in the meli-
oidosis and HH cohorts, we performed multicolor 
flow cytometry on WBA samples. In the melioidosis 
cohort, about half of the IFN-γ responses, on average, 
came from CD4 T cells for all 3 Burkholderia antigens 
(Figure 4), which was significantly higher than for the 
HH cohort (p<0.03), suggesting a strong contribution 
of antigen-specific memory responses (Appendix Fig-
ure 1, panels A, E). In contrast, the IFN-γ responses 
in the HH cohort were primarily driven by NK cells 
(about one third), followed by a balanced mix of 
Figure 2. Human humoral 
immune responses to 
Burkholderia pseudomallei, B. 
thailandensis, and BCTV by IgG 
and IgM ELISAs, Thailand. IgG-
specific (A) and IgM-specific (B) 
responses are shown for acute 
melioidosis patients (n = 73) and 
3 control cohorts, HH (n = 35), 
DM (n = 54), and OGNI (n = 10), 
against culture-filtrate antigen of 
B. pseudomallei, B. thailandensis, 
and BTCV. Each symbol 
represents an IgM or IgG antibody 
response from a patient. Medians 
(horizontal lines) and interquartile 
ranges (error bars) are shown. 
p values were calculated by 
using the nonparametric Mann-
Whitney test. Horizontal bars at 
top of figure indicate comparisons 
across cohorts. BTCV, B. 
thailandensis CPS variant; CPS, 
capsular polysaccharide; DM, 
patients with diabetes mellitus; 
HH, healthy household contacts of 
melioidosis case-patients.
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DN T, CD4 T, and other cells (Figure 4). In particu-
lar, the contribution of IFN-γ responses from DN T 
cells against all Burkholderia antigens in the HH co-
hort was significantly higher than in the melioidosis 
cohort (p<0.01) (Appendix Figure 1, panel C). In the 
melioidosis cohort, we observed a strong correlation 
of IFN-γ responses against B. pseudomallei, B. thailand-
ensis, and BTCV in CD4 T cells (ρ>0.8; p<0.01) (Ap-
pendix Table 5). In contrast, the HH cohort showed 
strong correlation between IFN-γ responses toward 
B. pseudomallei, B. thailandensis, and BTCV in CD8 T 
and NK cells (ρ>0.9; p<0.01) (Appendix Table 6).
Discussion
Our results demonstrate that melioidosis patients 
show strong humoral and cellular cross-immunity 
between the pathogenic B. pseudomallei and the less 
pathogenic B. thailandensis and BTCV. On the other 
hand, the HH cohort and control cohorts in general 
had relatively low humoral immune responses to all 
3 Burkholderia antigens but profound cellular immune 
responses. We showed that just over half of the acute 
melioidosis patients were positive by IHA; previous 
work in our group has shown that a significant pro-
portion (12.6%) of melioidosis patients never serocon-
vert (16). We do not have enough information to con-
firm whether the persistence of seropositivity against 
B. pseudomallei in healthy persons is associated with 
latent infection or with successful clearance of B. pseu-
domallei after exposure events.
Seropositivity against B. pseudomallei is associ-
ated with repeated environmental exposure to the 
organism (19). In addition, a recent epidemiologic 
study showed high prevalence of environmental 
B. pseudomallei in rice paddy fields across multiple 
regions of Thailand, especially in the east (6). Sub-
sequent serologic responses against B. pseudomallei 
in healthy rice farmers are associated with expo-
sure to environmental B. pseudomallei rather than 
B. thailandensis and BTCV (20); the cause could be a 
higher prevalence of B. pseudomallei. It is impossible 
to distinguish between the serologic responses to B. 
pseudomallei and BTCV because CPS components are 
highly cross-reactive (9).
Humoral immune responses against CPS compo-
nents have been found to be associated with protec-
tion against experimental melioidosis in mice (22,23). 
In a previous study, Tiyawisutsri et al. used modified 
IHA to detect cross-reactivity between B. pseudomal-
lei, B. thailandensis, and B. mallei, the causative agent 
of glanders, in melioidosis patients (24). Tiyawisutsri 
et al. reported poor cross-reactivity between B. pseu-
domallei and B. thailandensis and saw cross-reactivity 
to B. mallei, which expresses similar CPS components 
Figure 3. Ex vivo IFN-γ ELISpot 
responses to Burkholderia 
pseudomallei, B. thailandensis, 
and BTCV, Thailand. IFN-γ 
responses were quantified for 
acute melioidosis patients (n = 
82) and 3 control cohorts: HH, 
n = 93), diabetic patients (DM, 
n = 95), and patients with other 
gram-negative infections (OGNI, 
n = 42) against whole-cell heat-
killed antigens of Burkholderia 
pseudomallei (BP, red dots), 
Burkholderia thailandensis 
(BT, green diamonds), and 
Burkholderia thailandensis CPS 
variant (BTCV, blue triangles) are 
shown. Each symbol represents 
the average number of SFU per 
subject. Medians (horizontal 
lines) and interquartile ranges 
(error bars) are shown. p values 
were calculated by using the 
nonparametric Mann-Whitney 
test. Horizontal bars at top of 
figure indicate comparisons 
across cohorts. BTCV, B. 
thailandensis CPS variant; 
CPS, capsular polysaccharide; DM, patients with diabetes mellitus; HH, healthy household contacts of melioidosis case-patients; IFN-γ, 
interferon-γ; NS, not significant; SFU, spot-forming units.
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(24,25). Consistent with these findings, we report 
strong cross-reactivity between B. pseudomallei and 
BTCV, and to a lesser extent to B. thailandensis in the 
melioidosis and HH cohorts. Moreover, we suggest 
that the IHA responses may be primarily specific to 
CPS components that are not present in B. thailand-
ensis (9). We explored the humoral responses by IgM 
and IgG; we report strong IgG responses in acute 
melioidosis patients but marginal IgM responses. A 
possible cause of the low IgM responses in acute meli-
oidosis patients is that disease onset occurred some 
time before admission; reported incubation period is 
1–21 days (26). Another possibility is that preexisting 
immunity to B. pseudomallei resulted in a burst of IgG 
responses around the time of study enrollment, which 
is consistent with a previous report (27). Thus, the 
IgG ELISA could be an improved diagnostic method 
for melioidosis (28).
Cell-mediated immune responses by IFN-γ and 
type I immune responses (e.g., interleukin [IL] 12, 
IL-18, tumor necrosis factor α) are essential for the 
host immune system in fighting against intracellular 
infections (29–31). Nithichanon et al. showed that 
most of an exposed healthy population has acquired 
cellular immunity against broad immunogenic B. 
pseudomallei epitopes (32). Our IFN-γ ELISpot ex-
periments suggest that both melioidosis patients and 
HH contacts engage strong cross-immune IFN-γ re-
sponses between B. pseudomallei, B. thailandensis, and 
BTCV, despite low humoral responses in the HH co-
hort. The IFN-γ responses predominantly from T cells 
during melioidosis are associated with protection and 
survival against B. pseudomallei infection (13). We 
demonstrate that IFN-γ responses to all 3 antigens are 
a mix of T and NK cell responses, with different con-
tribution of T-cell subsets in the melioidosis cohort 
compared with the HH cohort. Whereas melioido-
sis patients predominantly exhibit CD4 T-cell IFN-γ 
responses, the HH cohort is characterized by a mix 
of double negative and CD4 T-cell responses and in-
creased NK cell responses, suggesting an innate or 
innate-like driven immune response.
Low-dose exposure to B. pseudomallei in healthy 
persons may also contribute to immune responses. 
B. pseudomallei–specific cellular immunity in sero-
negative healthy participants showed detectable 
IFN-γ ELISpot responses in some subjects to viru-
lent factors in B. pseudomallei, such as bopE (Type III 
secreted protein), pilO (Type IV pilus biosynthesis 
protein), and flgK (flagellar hook-associated protein) 
(12). Another possibility would be cross-reactivity 
to other gram-negative bacteria, as demonstrated 
by some OGNI participants exhibiting high IFN-γ 
responses to whole-cell heat-killed Burkholderia an-
tigens (Figure 3).
In a previous study in this population, we demon-
strated that acute melioidosis patients elicited strong 
cellular immune responses in both the CD4 and CD8 
T-cell compartments (13). Cellular immune responses 
by CD4 T cells against B. pseudomallei antigen (AhpC) 
have been associated with survival (33). HIV positiv-
ity does not seem to be a major risk factor for melioi-
dosis; a surge in melioidosis incidence and severity 
was not seen during the HIV epidemic in the 1990s in 
Figure 4. Cellular immune 
responses to Burkholderia 
pseudomallei, B. 
thailandensis, and BTCV 
by whole blood stimulation 
assay using flow cytometry 
between melioidosis patients 
and healthy persons in B. 
pseudomallei–endemic 
areas, Thailand. Whole blood 
samples from 14 patients 
with acute melioidosis and 8 
HH contacts were stimulated 
with culture-filtrate antigens 
of B. pseudomallei, B. 
thailandensis, BTCV, and SEB 
(positive control). Frequencies 
of CD4, CD8, and DN T cells; 
NK cells; and other cells 
within total IFN-γ–producing 
cells are shown. Medians 
were used to generate each vertical slice graph. BTCV, B. thailandensis CPS variant; CPS, capsular polysaccharide; DM, patients with 
diabetes mellitus; DN, double negative (CD4–CD8–); HH, healthy household contacts of melioidosis case-patients; IFN-γ, interferon-γ; 
SEB, Staphylococcus enterotoxin B.
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Thailand (34) although cases of tuberculosis and oth-
er opportunistic infections such as cryptococcal men-
ingitis did increase. During this time, 2.8% (95% CI 
0.8%–4.7%) of 286 patients in Ubon Ratchathani with 
B. pseudomallei tested positive for HIV, compared with 
0.6%–1.1% of blood donors, but this difference was 
not significant (35). However, HIV infection is known 
to increase the risk for other gram-negative infections, 
such as Salmonella and Escherichia coli, and it is like-
ly that a relationship between HIV and melioidosis 
could be demonstrated by sufficiently powered stud-
ies. To date, host immune responses by CD4 T cells 
in HIV-positive persons with melioidosis remain un-
known. Host immune responses during acute melioi-
dosis associated with survival have been shown to be 
dominated by CD8 T and NK cells (36,37), and some 
redundancy may occur to allow compensation of low 
CD4 counts in HIV.
In conclusion, patients with melioidosis in 
Thailand demonstrate immune cross-reactivity be-
tween B. pseudomallei, B. thailandensis, and BTCV in 
both humoral and cellular immune compartments. 
Healthy persons who live in melioidosis-endemic 
areas, on the other hand, primarily demonstrate cel-
lular immune cross-reactivity. We recommend fur-
ther investigation of human immune responses in 
healthy persons where the less pathogenic strains 
are prevalent, such as in the central and eastern 
parts of Thailand (20). It is possible that exposure to 
the less virulent B. thailandensis and BTCV generates 
immune cross-reactivity, which could confer some 
protection against melioidosis. Nevertheless, cross-
protection against B. pseudomallei infection through 
immune cross-reactivity in humans requires further 
study. Understanding the consequences of naturally 
acquired immunity to B. pseudomallei or B. thailand-
ensis variants in previously exposed populations is 
particularly needed for the development of an effica-
cious vaccine.
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